**Core tip:** Acquired factor V deficiency (AFVD) is a rare secondary hemorrhagic disease, which can lead to serious bleeding disorder. We report a new AVFD case of a hemodialysis patient with severe serous cavity hemorrhagic effusion, associated with potentially secondary to lymphatic leakage, and factor V inhibitor detection is negative. This is the first report regarding the association between coagulation factor V deficiency and lymphatic drainage in hemodialysis patient of chronic kidney disease patient. Careful follow-up of blood coagulation is needed in patients under the treatment of lymphatic drainage.

INTRODUCTION
============

Acquired factor V deficiency (AFVD) is a rare secondary hemorrhagic disease that can lead to a severe bleeding disorder. Streiff et al\[[@B1]\] reported AVFD for the first time in 1955. A recent literature review cited approximately 200 cases of AFVD\[[@B2]\]. AFVD is primarily due to the development of factor V inhibitors, *i.e*. antibodies against factor V. Exposure to bovine thrombin, antibiotics, surgical procedures, tumors, autoimmune diseases, infections, transplantations, and disseminated intravascular coagulation (DIC) may trigger factor V inhibitors in previously healthy patients\[[@B3]\].

The clinical symptoms of AFVD have been reported as variable, and range from asymptomatic to a severe bleeding disorder and thrombosis\[[@B4]\]. We report here a case of AVFD in a hemodialysis patient with a severe serous cavity hemorrhagic effusion secondary to lymphatic leakage, and no factor V inhibitor was detected. Even though the case occurred several years ago, we are of the opinion that the case is clinically meaningful. A large volume of lymphatic drainage can lead to a coagulation disorder, which may not arouse suspicion.

CASE PRESENTATION
=================

Chief complaints and history of illness
---------------------------------------

The patient was a 47-year-old man who was admitted to our hospital on 7 January 2011 with a 2-year history of recurrent edema of the eyelids and lower extremities and a 7-d history of shortness of breath and severe hypertension. He was hospitalized due to exacerbation of limb and scrotal edema, as well as decreased urine output. The patient had no previous medical history. There was no family history of hemorrhagic disease and chronic kidney disease (CKD).

Physical examination
--------------------

Physical examination revealed mild pitting edema in both lower extremities.

Laboratory examinations
-----------------------

Laboratory testing revealed the following: blood urea nitrogen, 60.26 mmol/L; serum creatinine, 1026 µmol/L; prothrombin time (PT), 14.3 s; active partial thrombin time (APTT), 40 s; hemoglobin, 63 g/L; white blood cell (WBC) count, 6.12 × 10^9^/L; neutrophilic granulocyte percentage (N%), 79.2%; and platelet count, 176 × 10^9^/L. Chest X-ray: Lung was negative. On 8 January 2011, a right femoral venous catheterization was performed to facilitate hemodialysis treatment. In the absence of ultrasonic guidance, the puncture needled the right femoral artery and resulted in a right common femoral artery pseudo aneurysm with a size of 63 mm × 37 mm. The patient received non-heparin dialysis during dialysis treatment. On 28 January 2011, after a right femoral artery pseudoaneurysm resection and rupture repair, the lump resolved. One week post-operatively, a gradually increasing 2 cm × 3 cm mass without swelling, tenderness, and a fluctuating sensation was not found in the medial aspect of the surgical incision with a light yellow clear liquid exudate on the surface. After a diagnostic puncture and catheterization, 500 mL of light red liquid was drained under negative pressure (Table [1](#T1){ref-type="table"}). A lymphatic fistula was diagnosed and the lymph liquid consisted of the following: WBC count, 3.0 × 10^6^/L; red blood cell (RBC) count, 44 × 10^6^/L; glucose, 7.31 mmol/L; total protein, 5.3 g/L; and lactate dehydrogenase, 88 g/L.

###### 

Laboratory test results for lymphatic fistula, pericardial and thoracic drainage fluids

                            **Lymphatic Fistula fluid**   **Pericardial fluid**   **Thoracic drainage fluid**
  ------------------------- ----------------------------- ----------------------- -----------------------------
  WBC (10^6^/L)             3                             4960                    3320
  RBC (10^9^/L)             44                            4620                    1380
  N (%)                     5                             70                      60
  Protein (g/L)             5.3                           56.7                    45.7
  GLU (mmol/L)              7.31                          3.15                    7.18
  LDH (U/L)                 88                            539                     261
  TB-Ab                     Negative                      Negative                Negative**/**Positive
  Bacterial growth smear    Negative                      Negative                Negative
  Acid-fast bacilli smear   Negative                      Negative                Negative

WBC: White blood cell; RBC: Red blood cell; N%: Neutrophilic granulocyte percentage; GLU: Glucose; LDH: Lactate dehydrogenase; TB-Ab: Tuberculosis antibody

Five days later, the coagulation time was significantly prolonged after lymphatic drainage on the right side; a vitamin K1 supplement proved ineffective. The hemoglobin level was significantly decreased and the patient had a small amount of nasal mucosa bleeding and large bloody pericardial and pleural effusions. Laboratory testing revealed the following: albumin, 35.7 g/L; PT, 52.8 s; APTT, 180.1 s; fibrinogen, 4.67 g/L; coagulation factor II, 72%; coagulation factor VII, 84%; and coagulation factor X, 64% (Table [2](#T2){ref-type="table"}). Factor V was deficient (2% of population average) and no inhibitor was detected. A total of 1140 mL of fluid was drained by pericardial aspiration, with a red and turbid appearance. In addition, 2400 mL of fluid was drained *via* thoracic drainage and had a deep red appearance without clots. Fluid cultures were obtained and negative.

###### 

Time course of levels of coagulation factors and function

             **Normal range**   **February 23, 2011**   **March 3, 2011**   **March 24, 2011**   **April 20, 2011**   **March 13, 2018**
  ---------- ------------------ ----------------------- ------------------- -------------------- -------------------- --------------------
  PT (s)     11.0-15.0          52.8                    29.2                18.9                 16.2                 
  PT (%)     70-120             13                      27                  58.4                 67                   
  PT-INR                        6.15                    2.82                1.85                 1.29                 
  APTT (s)   31.5-43.5          180.1                   86.8                49.2                 49                   
  TT (s)     14-21              15.6                                                                                  
  Fib        2.00-4.00          4.67                                                                                  
  FII (%)    70-120             72                                                                                    
  FV (%)     70-120             2                       8                   15                   46                   98.9
  FVII (%)   70-120             84                                                                                    
  FX (%)     70-120             64                                                                                    
  PC:AC      70-120             92                                                                                    

PT: Prothrombin time; APTT: Active part thrombin time; TT: Thrombin time; Fib: Fibrinogen; FII: Coagulation factor II; FV: Coagulation factor V; FVII: Coagulation factor VII; FX: Coagulation factor X; PC: Protein C.

FINAL DIAGNOSIS
===============

The final diagnosis is AFVD and chronic kidney disease stage 5D.

TREATMENT
=========

The main treatment measures included maintenance hemodialysis, supplementing fresh frozen plasma, and reducing the lymphatic drainage.

Since 5 February 2011, the patient has received treatment with a daily infusion of 200-600 mL of fresh frozen plasma. After applying a pressure dressing, the lymphatic drainage decreased, the skin bleeding resolved, the pericardial and pleural effusions decreased, coagulation function improved, and PT and APTT decreased. On 3 March 2011, the coagulation factor V level was 8% (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). On 20 April 2011, coagulation factor V level improved (to 46%). The amount of lymph drainage was correlated with the PT and APTT.

![The amount of lymph drainage (A), the values of active partial thrombin time and prothrombin time (B) at the different time. APTT: Active partial thrombin time; PT: Prothrombin time.](WJCC-7-2556-g001){#F1}

OUTCOME AND FOLLOW-UP
=====================

The patient improved clinically and coagulation factor V level (to 46%) after the follow-up for three months. On 13 March 2018, coagulation factor V level was 98.9%.

DISCUSSION
==========

We report a patient with chronic kidney disease who exhibited mucosal hemorrhage and multiple hemorrhagic effusions in the serous cavity associated with lymphatic leakage due to acquired coagulation factor V deficiency (Figure [1](#F1){ref-type="fig"}).

The patient had no exposure to bovine thrombin and no manifestations of DIC. There was no history of antibiotic use and no evidence of antibiotics contributing to the coagulant function abnormality. AVFD occurred two weeks after surgery, but there was no direct evidence of an association with the surgical procedure. The patient had no autoimmune diseases previously reported which could have led to AVFD.

In this case, the lymphatic vessel injury caused lymphatic leakage. Negative pressure drainage has been reported to be a method to treat lymphatic leakage\[[@B5]\]. After constant lymphatic drainage, the patient exhibited significant malnutrition, weight loss of approximately 10 kg, and decreased serum albumin and immunoglobulin concentrations. Biochemical testing revealed the existence of clotting factor deficiency that may have been due to immune dysfunction caused by persistent lymphatic drainage, or coagulation inhibitor production and coagulation inhibitor partly cleared by hemodialysis, resulting in no detection of inhibitors\[[@B3],[@B6]\]. The lymphmay also be due to lymphatic drainage of the clotting factors rather than immune factors with producing an inhibitor, but the composition of the lymphatic drainage was not tested.

Coagulation function was improved after supplementation by fresh frozen plasma. Eight days after reduced drainage following the application of a pressure dressing, coagulation factor V concentration increased to 8%, the bleeding tendency and bloody effusions in the pericardial and pleural cavities were resolved, and after removal of the drainage tube, coagulation factor V concentration increased to 46%. It has been reported that high-dose immunoglobulin treatment rapidly improved coagulation factor V deficiency caused by immune disorder\[[@B6]\]. The patient in the current study was treated with human immunoglobulin (10 g/d for four consecutive days) from 25 February 2011, which was ineffective. Because no coagulation factor inhibitors were detected, hormone and immunosuppressive drugs were not used\[[@B7]\].The amount of lymph drainage was positively correlated with the PT and APTT values, indicating that there was a quantitative relationship between the amount of lymph drainage and coagulation function (coagulation factor V deficiency).

CONCLUSION
==========

This is the first report regarding an association between coagulation factor V deficiency and lymphatic drainage in a chronic kidney disease patient for hemodialysis. Careful follow-up of blood coagulation is needed in patients under treatment with lymphatic drainage associated with various diseases and operation.
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